Emerging biological therapies for systemic lupus erythematosus. - Wikidata - wikimedia - TriplyDB

Emerging biological therapies for systemic lupus erythematosus.

Emerging biological therapies for systemic lupus erythematosus.

http://www.wikidata.org/entity/Q38192683

about

Decrease of Functional Activated T and B Cells and Treatment of Glomerulonephitis in Lupus-Prone Mice Using a Natural Flavonoid Astilbin Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date Current role of rituximab in systemic lupus erythematosus.Towards new avenues in the management of lupus glomerulonephritis.Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.Con: Cyclophosphamide for the treatment of lupus nephritis.Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus.Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.Axl, Ferritin, Insulin-Like Growth Factor Binding Protein 2, and Tumor Necrosis Factor Receptor Type II as Biomarkers in Systemic Lupus Erythematosus.Treat-to-target in systemic lupus erythematosus: are we there yet?Validation of the LupusPRO in Chinese patients from Hong Kong with systemic lupus erythematosus.

P2860

Q35389559-60751537-438E-4655-8BD8-6CE84975BBA4 Q37709763-7954A9A9-184D-483F-B38E-2F8EA8C00A20 Q38293284-90A0BAE1-E1C9-4A1E-AD1A-0CBE7D51C00A Q38686467-354AE14D-2877-4C4F-8195-1C10ED3F85CC Q38690844-829575F7-DC8B-4650-9C10-7DE11278A486 Q38837080-00AA7B58-3E4F-4FFF-B2E6-FB3B0CA2A1CD Q38897055-FAA58DAA-DC57-466E-AE8A-4D6B3DD95FB7 Q41915986-D94EA856-F6FE-449D-BF61-B5CB02131A94 Q42134678-B70EFB20-CE16-47CE-9C66-1B6BA55FAA43 Q47846085-F815A6B8-BA31-4728-9358-C0CCA66957D4 Q48067173-F9784172-2373-4B7F-875C-5A1B607B3A67

P2860

Emerging biological therapies for systemic lupus erythematosus.

http://www.wikidata.org/entity/Q38192683

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Emerging biological therapies for systemic lupus erythematosus.

@en

type

label

Emerging biological therapies for systemic lupus erythematosus.

@en

prefLabel

Emerging biological therapies for systemic lupus erythematosus.

@en

P1433

Q38192683-CC76D469-F3F3-4DD3-8676-B93FE583C8D4

P1476

Q38192683-752B6F39-004D-4517-A82E-4EC2CABAC2E0

P2093

Q38192683-EC68BEB9-C855-4AD7-96E9-920C562704F2

P2860

Q38192683-02746AE5-2933-4AF7-B0F7-4E04C55D4951

Q38192683-093437AC-3AA9-471B-B1CC-D9DCFB9E62BD

Q38192683-0B079FC5-BF17-4D9F-A232-FBC4FFC8035D

Q38192683-0D2541F9-DBFF-42BD-B2B6-D8BE45A9A24F

Q38192683-0E26F9F1-4A9B-4385-8C85-805ADCD91E28

Q38192683-0F2A78F9-3443-40B3-A231-B8C7D8B3C24E

Q38192683-0F7A8759-BB50-43FA-91AC-6740CC0CEE68

Q38192683-18E684FE-AA56-45DC-97B6-B1F8861E9D43

Q38192683-193780F0-018A-4494-8AE3-7AA5131EBE26

Q38192683-1A854236-966C-407F-A554-9E0B1605B8FF

P304

Q38192683-EB8F9745-644C-475D-BEC5-03CA752F66A3

P31

Q38192683-EFE81E41-D797-4EF1-8F32-7E84E780D7E8

P356

Q38192683-CCA7CDDA-57D6-4891-A2D9-3E7B109F091C

P407

Q38192683-122A4E8D-87B9-4757-8AC3-D4E43722CF1A

P433

Q38192683-9D0FECAB-B951-4D34-B3A5-65242304761C

P478

Q38192683-D039A52A-C48E-42E5-999E-90B5B1992E7E

P577

Q38192683-87005339-22E1-4137-813D-DA68DFC75296

P698

Q38192683-4E2D797D-5309-4F37-8B09-461AACA028AC

P356

14728214.2014.894018

P1433

Expert Opinion on Emerging Drugs

P1476

Emerging biological therapies for systemic lupus erythematosus.

@en

P2093

Chi Chiu Mok

http://www.w3.org/2001/XMLSchema#string

P2860

Pathogenesis of systemic lupus erythematosus

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus

Belimumab for systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.

Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.

P304

303-322

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728214.2014.894018

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24588398

http://www.w3.org/2001/XMLSchema#string